Experienced in Denys-Drash Syndrome (DDS)

Dr. Aerang S. Kim

Pediatric Hematology Oncology

10 Center Dr, Building 10, Crc, Rm 1-3872,

Bethesda, MD

Experienced in Denys-Drash Syndrome (DDS)

10 Center Dr, Building 10, Crc, Rm 1-3872,

Bethesda, MD

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Aerang Kim is a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Kim is rated as an Experienced provider by MediFind in the treatment of Denys-Drash Syndrome (DDS). Her top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Rhabdomyosarcoma.

Her clinical research consists of co-authoring 66 peer reviewed articles and participating in 28 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 4 clinical trials in the study of Denys-Drash Syndrome (DDS).

Specialties

Pediatric Hematology Oncology

Licenses

Pediatric Hematology-Oncology in MD

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem

Blue Cross Blue Shield

CareFirst

Cigna

Humana

HMO
INDEMNITY
POS
PPO

Independent Health

Managed Medicaid

OTHER MANAGED MEDICAID

Medicaid

OTHER MEDICAID
STATE MEDICAID

Medicare

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE PART D

Premera Blue Cross

INSURANCE PLAN
MEDICARE MAPD
OTHER COMMERCIAL
PPO

UnitedHealthcare

View 7 Less Insurance Carriers -

Locations

10 Center Dr, Building 10, Crc, Rm 1-3872, Bethesda, MD 20892

Call: 301-451-7025

Additional Areas of Focus

Dr. Kim has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

28 Clinical Trials

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

Enrollment Status: Active_not_recruiting

Publish Date: December 08, 2025

Intervention Type: Drug

Study Drugs: Ramucirumab, Cyclophosphamide, Vinorelbine

Study Phase: Phase 1/Phase 2

Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Drug

Study Drug: Larotrectinib Sulfate

Study Phase: Phase 2

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Drug, Other

Study Drugs: Cabozantinib, Cabozantinib-S-Malate

Study Phase: Phase 2

A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults With Recurrent HER2+ Osteosarcoma

Enrollment Status: Suspended

Publish Date: October 31, 2025

Intervention Type: Biological, Procedure

Study Drug: Trastuzumab Deruxtecan

Study Phase: Phase 2

A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Enrollment Status: Active_not_recruiting

Publish Date: October 29, 2025

Intervention Type: Procedure, Drug

Study Drug: Trametinib

Study Phase: Phase 2

An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) With an Isocitrate Dehydrogenase-2 (IDH2) Mutation

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Procedure, Drug

Study Drugs: Enasidenib, Enasidenib Mesylate

Study Phase: Phase 2

A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation

Enrollment Status: Terminated

Publish Date: October 02, 2025

Intervention Type: Drug

Study Drug: Ponatinib

Study Phase: Phase 1/Phase 2

A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: September 23, 2025

Intervention Type: Biological

Study Drug: CAB-AXL-ADC

Study Phase: Phase 1/Phase 2

A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: August 08, 2025

Intervention Type: Drug

Study Drug: Elimusertib

Study Phase: Phase 1/Phase 2

A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: August 07, 2025

Intervention Type: Drug

Study Drug: APG-115+Pembrolizumab

Study Phase: Phase 1/Phase 2

A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Enrollment Status: Completed

Publish Date: April 13, 2025

Intervention Type: Drug

Study Drugs: Azacitidine, Cytarabine, Fludarabine Phosphate, Methotrexate, Pevonedistat, Hydrocortisone

Study Phase: Phase 1

A Phase 1 / 2, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma

Enrollment Status: Terminated

Publish Date: February 12, 2025

Intervention Type: Drug

Study Drug: TK216

Study Phase: Phase 1/Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Other, Drug

Study Drug: Vemurafenib

Study Phase: Phase 2

A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Enrollment Status: Completed

Publish Date: January 14, 2025

Intervention Type: Drug, Other

Study Drug: Selinexor

Study Phase: Phase 1

A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan

Enrollment Status: Completed

Publish Date: January 14, 2025

Intervention Type: Drug, Other

Study Phase: Phase 1

A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Enrollment Status: Active_not_recruiting

Publish Date: January 09, 2025

Intervention Type: Drug, Biological

Study Drugs: Cytarabine, Flotetuzumab

Study Phase: Phase 1

Safety and Feasibility Study of Using MR-guided High Intensity Focused Ultrasound (HIFU) for the Ablation of Relapsed or Refractory Pediatric Solid Tumors

Enrollment Status: Completed

Publish Date: January 01, 2025

Intervention Type: Device

Study Phase: Phase 1

A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors

Enrollment Status: Completed

Publish Date: October 22, 2024

Intervention Type: Drug

Study Drugs: Irinotecan, Pevonedistat, Temozolomide

Study Phase: Phase 1

A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors

Enrollment Status: Completed

Publish Date: July 15, 2024

Intervention Type: Biological, Other

Study Drug: Pepinemab

Study Phase: Phase 1/Phase 2

A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas

Enrollment Status: Completed

Publish Date: January 31, 2024

Intervention Type: Drug, Other, Radiation

Study Drug: Adavosertib

Study Phase: Phase 1

SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors

Enrollment Status: Completed

Publish Date: December 26, 2023

Intervention Type: Drug

Study Drugs: Selumetinib, Sirolimus

Study Phase: Phase 2

A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors

Enrollment Status: Completed

Publish Date: December 20, 2023

Intervention Type: Other, Drug

Study Phase: Phase 1

A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Enrollment Status: Completed

Publish Date: October 17, 2023

Intervention Type: Drug, Other

Study Drug: Entinostat

Study Phase: Phase 1

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma

Enrollment Status: Terminated

Publish Date: September 13, 2023

Intervention Type: Drug

Study Drugs: Ramucirumab, Gemcitabine, Docetaxel

Study Phase: Phase 1/Phase 2

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Relapsed or Refractory Solid Tumors in Children, Adolescents, and Young Adults

Enrollment Status: Terminated

Publish Date: August 29, 2023

Intervention Type: Drug, Device

Study Drug: Lyso-Thermosensitive Liposomal Doxorubicin

Study Phase: Phase 1

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas

Enrollment Status: Terminated

Publish Date: August 01, 2022

Intervention Type: Other, Drug

Study Phase: Phase 2

A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors

Enrollment Status: Completed

Publish Date: August 17, 2021

Intervention Type: Drug

Study Phase: Phase 1

A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors

Enrollment Status: Completed

Publish Date: May 20, 2020

Intervention Type: Drug

Study Phase: Phase 1

View 27 Less Clinical Trials

Similar Doctors

Advanced in Denys-Drash Syndrome (DDS)

Dr. Jeffrey S. Dome

Pediatric Hematology Oncology

Advanced in Denys-Drash Syndrome (DDS)

Dr. Jeffrey S. Dome

Pediatric Hematology Oncology

111 Michigan Ave Nw, Children's National Medical Center,

Washington, DC

(7.1 miles away)

202-476-2800

Languages Spoken:

English

See accepted insurances

Jeffrey Dome is a Pediatric Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Dome is rated as an Advanced provider by MediFind in the treatment of Denys-Drash Syndrome (DDS). His top areas of expertise are Rhabdoid Tumor, Denys-Drash Syndrome (DDS), Neuroblastoma, Nephrectomy, and Bone Marrow Aspiration.

Advanced in Denys-Drash Syndrome (DDS)

Dr. Jason M. Fixler

Pediatric Hematology Oncology

Advanced in Denys-Drash Syndrome (DDS)

Dr. Jason M. Fixler

Pediatric Hematology Oncology

Sinai Hospital Of Baltimore, Inc

2401 E Belvedere Ave,

Baltimore, MD

(32.7 miles away)

410-601-5303

Languages Spoken:

English

See accepted insurances

Jason Fixler is a Pediatric Hematologist Oncology provider in Baltimore, Maryland. Dr. Fixler is rated as an Advanced provider by MediFind in the treatment of Denys-Drash Syndrome (DDS). His top areas of expertise are Sickle Cell Disease, Hepatoblastoma, Ewing Sarcoma, Reticulohistiocytoma, and Bone Marrow Aspiration.

Experienced in Denys-Drash Syndrome (DDS)

Dr. Anne B. Warwick

Pediatric Hematology Oncology

Experienced in Denys-Drash Syndrome (DDS)

Dr. Anne B. Warwick

Pediatric Hematology Oncology

8901 Wisconsin Ave, Wrnmmc, Peds Heme/onc, 4th Floor Bldg 19/america Bldg,

Bethesda, MD

(0.6 miles away)

301-400-1663

Languages Spoken:

English

See accepted insurances

Anne Warwick is a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Warwick is rated as an Experienced provider by MediFind in the treatment of Denys-Drash Syndrome (DDS). Her top areas of expertise are Denys-Drash Syndrome (DDS), Leukemia, Acute Lymphoblastic Leukemia (ALL), Nephrectomy, and Bone Marrow Transplant.

VIEW MORE DENYS-DRASH SYNDROME (DDS) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kim's expertise for a condition

ConditionClose